

The Critical Path Institute Podcast: 20 Years of Impact Reflect on C-Path's Legacy and a Look Ahead, Pt. 1

This Critical Path Institute (C-Path) podcast episode celebrates C-Path's 20 years of impactful innovation, and looks at the future of accelerating drug development by connecting scientific, clinical, regulatory, and data-driven disciplines. Founded in 2005 in response to the FDA's 2004 Critical Path Initiative, C-Path was established as a neutral, nonprofit organization to facilitate public-private partnerships involving industry, academia, patient groups, and regulators. These partnerships aim to identify bottlenecks in drug development and create actionable scientific solutions that make the process more efficient for all stakeholders.

Over the past two decades, C-Path has transformed challenging therapeutic areas—such as Alzheimer's disease, rare diseases like Duchenne muscular dystrophy and Friedreich's ataxia, tuberculosis, polycystic kidney disease, type 1 diabetes prevention, irritable bowel syndrome, and myelodysplasia—from stagnant or neglected fields into thriving areas with new drug approvals and robust development pipelines. Building on these successes, C-Path looks to scale to materialize more meaningful impact for people in need, driven by integrating diverse data sources (clinical trials, observational studies, patient registries, electronic health records) into comprehensive platforms, enabling the development and qualification of biomarkers, clinical outcome assessments, and quantitative modeling tools.

Join C-Path CEO Klaus Romero and President/COO Kristen Swingle in Part One of this podcast for a final celebration of our 20 years of impact and vision going forward.